Episurf Medical (Nasdaq: EPIS B), a pioneer and leader in individualised technologies for painful joint injuries, today announces that the Episealer® knee implants have been registered and approved for sale in Italy. The company is also in the final stages of establishing distribution in the Lombardia region as a first step.
“We have identified the Italian market as an attractive market, and we have now completed a local regulatory registration process. We have attended industry congresses in Italy, and had Italian visitors at our masterclass in Stockholm in June. There is a genuine interest in our implant technology, and we look forward to offering the Episealer® to Italian surgeons and patients” says Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.10 CEST on 4 September 2019.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] =>
[HtmlContact:protected] =>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">Episealer® knee implant approved for sale in Italy</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => Episurf Medical (Nasdaq: EPIS B), a pioneer and leader in individualised technologies for painful joint injuries, today announces that the Episealer® knee implants have been registered and approved for sale in Italy. The company is also in the final stages of establishing distribution in the Lombardia region as a first step.
“We have identified the Italian market as an attractive market, and we have now completed a local regulatory registration process. We have attended industry congresses in Italy, and had Italian visitors at our masterclass in Stockholm in June. There is a genuine interest in our implant technology, and we look forward to offering the Episealer® to Italian surgeons and patients” says Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.10 CEST on 4 September 2019.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Episurf Medical (Nasdaq: EPIS B), a pioneer and leader in </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">individualised</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> technologies for painful joint injuries, today announces that the Episealer® knee implants have been registered and approved for sale in Italy. The company is also in the final stages of establishing distribution in the </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Lombardia</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> region as a first step. </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span> </p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><em><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">“We have identified the Italian market as an attractive market, and we have now completed a local regulatory registration process. We have attended industry congresses in Italy, and had Italian visitors at our masterclass in Stockholm in June. There is a genuine interest in our implant technology, and we look forward to offering the Episealer® to Italian surgeons and </span></em></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><em><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">patients”</span></em></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> says Pål Ryfors, CEO, Episurf Medical. </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span> </p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Tel:</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.10 CEST on 4 September 2019.</em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => S6
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 428
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/2895814/1100381.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Episealer® knee implant approved for sale in Italy
[Description:protected] => Episealer® knee implant approved for sale in Italy
[CreateDate:protected] => 2019-09-04T10:10:04Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3402461
[EncryptedId:protected] => CF7B9E9BBDD83056
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2019-09-04T10:10:00Z
[LastChangeDate:protected] => 2019-09-04T10:10:04Z
[Title:protected] => Episealer® knee implant approved for sale in Italy
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/episealer-knee-implant-approved-for-sale-in-italy,c2895814
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)